d-Fenfluramine in panic disorder: A dual role for 5-hydroxytryptamine

Psychopharmacology

Volumn 149, Issue 3, 2000, Pages 251-258

  Mortimore, C ^a   Anderson, I M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5 Hydroxytryptamine; Anxiety disorder; Cortisol; D Fenfluramine; Panic disorder; Prolactin

Indexed keywords

DEXFENFLURAMINE; PLACEBO; PROLACTIN; SEROTONIN;

ADULT; AGORAPHOBIA; ANXIETY; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; PANIC; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SEROTONIN RELEASE;

ADULT; ANALYSIS OF VARIANCE; ANXIETY; CARBON DIOXIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FENFLURAMINE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0034063330     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002139900342     Document Type: Article

References (65)

1. Anderson IM, Deakin JF, Miller HE (1996) The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers. Psychopharmacology 128:74-82
2. Andrews TM, Anderson IM (1998) Information processing in anxiety: a pilot study of the effect of manipulating 5-HT function. J Psychopharmacol 12:155-160
3. Audi EA, de Aguiar JC, Graeff FG (1988) Mediation by serotonin of the antiaversive effect of zimelidine and propranolol injected into the dorsal midbrain central grey. Psychopharmacology 2:26-32
4. Bandelow B (1995) Assessing the efficacy of treatments for panic disorder. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 10:73-81
5. Bandelow B, Hajak G, Holzrichter S, Kunert HJ, Ruther E (1995) Assessing the efficacy of treatments for panic disorder. I. Methodological problems. Int Clin Psychopharmacol 10:83-93
6. Bertani A, Perna G, Arancio C, Caldirola D, Bellodi L (1997) Pharmacologie effect of imipramine, paroxetine and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol 17:97-101
7. Black DW, Wesner R, Bowers W, Gabel J (1993) A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50:44-50
8. Blier P, de Montigny C (1994) Current advances in the treatment of depression. Trends Pharmacol Sci 15:220-226
9. Boyer W, Feighner JP (1998) The utility of SSRIs in anxious depression. In: Montgomery SA, den Boer JA (eds) SSRIs in depression and anxiety. Wiley, Chichester, pp 101-113
10. Campbell DB (1991) Dexfenfluramine: an overview of its mechanisms of action. Rev Contemp Pharmacother 2:93-113
11. Ceulemans DLS, Hoppenbrouwers HJA, Gelders YG, Reyntjens AJM (1985) The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18:303-305
12. Chambless DL, Caputo GC, Bright P, Gallagher R (1984) The assessment of fear in agoraphobics: the Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. J Consult Clin Psychol 52:1090-1097
13. Charney DS, Heninger GR (1987) Serotonin function in anxiety. II Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology 92:14-24
14. Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B et al. (1986) Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam and trazodone. J Clin Psychiatry 47:580-586
15. Coryell W (1997) Hypersensitivity to carbon dioxide as a disease-specific trait marker. Biol Psychiatry 41:259-263
16. 1A agonists in anxiety and depression. J Psychopharmacol 7:283-289
17. Deakin JFW, Graeff FG (1991) 5-HT and mechanisms of defence. J Psychopharmacol 5:305-315
18. Deakin JFW, Guimaraes FS, Graeff FG (1994) Testing 5HT theories of anxiety in normal volunteers. In: Palomo T, Archer T (eds) Strategies for studying brain disorders. Volume 1. Depressive, anxiety and drug abuse disorders. Farrand Press, London, pp 211-238
19. den Boer JA, Westenberg HGM (1988) Effect of serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3:59-74
20. den Boer JA, Westenberg HGM (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102:85-93
21. den Boer JA, Westenberg HGM, Kamerbeek WDJ (1987) Effect of serotonin uptake inhibitors in anxiety disorders, a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 2:21-32
22. Dillon DJ, Gorman JM, Liebowitz MR, Fyer AJ, Klein DF (1987) Measurement of lactate induced panic anxiety. Psychiatry Res 20:97-105
23. Dratcu L, Bond A (1993) Audit: referrals for panic disorder to a clinical psychopharmacology research unit. Psychiatr Bull 17:416-417
24. Evans, L, Kenardy, J, Schneider P, Hoey H (1986) Effects of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. Acta Psychiatr Scand 73:49-50
25. Goetz RR, Klein DF, Gorman JM (1994) Consistencies between recalled panic and lactate-induced panic. Anxiety 1:31-36
26. Goodall EM, Cowen PJ, Franklin M, Silverstone T (1993) Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology 112:461-466
27. Gorman JM, Fyer MR, Goetz R, Askanazi J, Leibowitz MR, Fyer AJ et al. (1988) Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry 45:31-39
28. 2 and hyperventilation in patients with panic disorder. Am J Psychiatry 151:547-553
29. Graeff FG, Viana MB, Mora PO (1997) Dual role of 5-HT in defense and anxiety. Neurosci Biobehav Rev 21:791-799
30. 2 as a marker of panic in severe anxiety. Am J Psychiatry 145:796-797
31. Guy W (1976) CGI. In: ECDEU assessment manual for psychopharmacology. DHEW Publication, revised no. (ADM), pp 76-338
32. Hamik A, Peroutka SJ (1989) 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 25:569-575
33. Handley SL (1991) Serotonin in animal models of anxiety: the importance of stimulus and response. In: Idzikowski C, Cowen PJ (eds) Serotonin, sleep and mental disorder. Wrightson, London, pp 89-115
34. Handley SL, McBlane JW (1993) 5-HT drugs in animal models of anxiety. Psychopharmacology 112:13-20
35. Hodges H, Green S, Glenn B (1987) Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not in discrimination. Psychopharmacology 92:491-504
36. Hoehn-Saric R, McLoed DR, Hipsley PA (1993) Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 13:321-326
37. Hollander E, Leibowitz MR, DeCavia, CM, Klein DF (1990) Fenfluramine, cortisol and anxiety. Psychiatry Res 31:211-213
38. 2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol 8:161-168
39. Kahn RS, Wetzler, S, van Praag HM, Asnis, GM (1988a) Behavioural indications of a serotonergic supersensitivity in panic disorder. Psychiatry Res 25:101-104
40. Kahn RS, Asnis GM, Wetzler S, van Praag HM (1988b) Neuroendocrine evidence for serotonin hypersensitivity in panic disorder. Psychopharmacology 96:360-364
41. Klein DF (1993) False suffocation alarms, spontaneous panics, and related conditions. Arch Gen Psychiatry 50:306-317
42. Laakmann G, Schule C, Lorkowski G, Baghai T, Kuhn K, Ehren traut S (1998) Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology 136:357-366
43. Marks IM, Mathews AM (1979) Brief standard self rating for phobic patients. Behav Res Ther 17:263-267
44. McNair DM, Lorr M, Droppleman LF (1971) Manual for the profile of mood states. Educational and Industrial Testing Service, San Diego, Calif.
45. 2-induced anxiety in panic disorder patients and normal volunteers. Br J Psychiatry 176:182-188
46. Montgomery A, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389
47. Napoliello MJ, Domantay AG (1991) Buspirone: a worldwide update. Br J Psychiatry 159:40-44
48. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J et al. (1995) Paroxetine in the treatment of panic disorder - a randomised double-blind placebo controlled study. Br J Psychiatry 167:374-379
49. Papp LA, Goetz R, Cole R, Klein DF, Jordan F, Leibowitz MR, Fyer AJ, Hollander E, Gorman JM (1989) Hypersensitivity to carbon dioxide in panic disorder. Am J Psychiatry 146:779-781
50. 2 in healthy first-degree relatives of patients with panic disorder. Am J Psychiatry 152:623-625
51. 2 in patients with panic disorder. Am J Psychiatry 153:1060-1064
52. Perna G, Bertani A, Gabriele A, Politi E, Bellodi L (1997) Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double blind, randomized, placebo controlled trial. J Clin Psychopharmacol 17:173-178
53. Quested DJ, Sargent PA, Cowen PJ (1997) SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology 133:305-308
54. Ramos RT, Gentil V, Gorenstein C (1993) Clomipramine and initial worsening in panic disorder: beyond the "jitteriness syndrome". J Psychopharmacol 7:265-269
55. Sanderson WC, Wetzler S (1990) Five percent carbon dioxide as a valid analogue and marker of panic disorder? Biol Psychiatry 27:689-701
56. Sanderson WC, Rapee RM, Barlow DH (1988) Panic induction via inhalation of 5.5% carbon dioxide enriched air: a single subject analysis of psychological and physiological effects. Behav Res Ther 26:333-335
57. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E (1993) The relative efficacy of high dose buspirone and alprazolam in the treatment of panic disorder: a double blind placebo-controlled study. Acta Psychiatr Scand 88:1-11
58. Solyom L (1994) Controlling panic attacks with fenfluramine. Am J Psychiatry 151:621-622
59. Spielberger CS, Gorsuch RL, Lushene RE (1970) Manual for the state-trait anxiety inventory. Consulting Psychologists Press, Palo Alto, Calif.
60. Spitzer RL, Williams JBW, Gibbon M, First MB (1990) Structured clinical interview for DSM III-R patient edition (SCID-P version 1.0). American Psychiatric Press, Washington, D.C.
61. Stahl SM, Hauger RL, Rausch JL, Fleishaker JC, Hubbell Alberts E (1993) Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol 16:819-31
62. Targum SD (1990) Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol Psychiatry 28:21-34
63. Targum SD (1991) Panic attack frequency and vulnerability to anxiogenic challenge studies. Psychiatry Res 36:75-83
64. Targum SD, Marshall LE (1989) Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28:295-306
65. Woods SW, Charney DS, Goodman WK, Heninger GR (1988) Carbon dioxide-induced anxiety. Arch Gen Psychiatry 45:43-52